Eosinophilic granulomatosis with polyangiitis present and future

Rheumatology key messagesThere is now a scientific rationale for biologic therapies based on our understanding of the pathogenesis of EGPA. Anti-IL5 therapy is improving outcomes in refractory and relapsing EGPA as evidenced by data with mepolizumab from the MIRRA trial.Rituximab has demonstrated efficacy in retrospective studies for relapsing and refractory disease and may be more effective in the ANCA-positive EGPA subgroup.Cyclophosphamide and GC therapy remain the therapy of choice for life or organ-threatening disease.

Source: Rheumatology - June 16, 2021 Category: Rheumatology Source Type: research